Aichi Cancer Center ( Site 2601)

Nagoya, Aichi-ken 464-8681

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer

Studies at this site

• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) — Running, not enrolling